However, patients with HER2-enriched disease and TNBC presented with more advanced disease at initial diagnosis (P<0.001), had a higher probability of receiving chemotherapy, and had higher mortality rates when compared with patients with luminal A breast cancers (Table 2 and Fig. 1). This evidence concerns the gene ERBB2 and breast carcinoma.